Genetic Variation Determines PPARγ Function and Anti-diabetic Drug Response In Vivo
暂无分享,去创建一个
Kyoung-Jae Won | B. Voight | M. Lazar | Ying Wu | D. Steger | L. Everett | M. Civelek | R. Soccio | M. J. Emmett | Erika R. Briggs | Hee-Woong Lim | Bin Fang | J. DiSpirito | Satyajit R. Rajapurkar | Eric R. Chen | Pegah Safabakhsh | Jill M. Marinis | Ying Wu | Ying Wu
[2] Tamara S. Roman,et al. New genetic loci link adipose and insulin biology to body fat distribution , 2014, Nature.
[3] Ankur Roy,et al. Circadian Enhancers Coordinate Multiple Phases of Rhythmic Gene Transcription In Vivo , 2014, Cell.
[4] M. Lazar,et al. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.
[5] M. Daly,et al. Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants , 2014, Nature.
[6] B. Peters,et al. Personalized pharmacogenomics profiling using whole-genome sequencing. , 2014, Pharmacogenomics.
[7] W. Sadee,et al. Missing heritability of common diseases and treatments outside the protein-coding exome , 2014, Human Genetics.
[8] Kyoung-Jae Won,et al. Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers , 2014, Genes & development.
[9] T. Meehan,et al. An atlas of active enhancers across human cell types and tissues , 2014, Nature.
[10] S. Mandrup,et al. Peroxisome Proliferator-Activated Receptor γ and C/EBPα Synergistically Activate Key Metabolic Adipocyte Genes by Assisted Loading , 2013, Molecular and Cellular Biology.
[11] A. Dunning,et al. Beyond GWASs: illuminating the dark road from association to function. , 2013, American journal of human genetics.
[12] M. Lazar,et al. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ , 2013, Proceedings of the National Academy of Sciences.
[13] Jonathan K. Pritchard,et al. The Functional Consequences of Variation in Transcription Factor Binding , 2013, PLoS genetics.
[14] C. Glass,et al. Impact of natural genetic variation on enhancer selection and function , 2013, Nature.
[15] Tanya M. Teslovich,et al. Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.
[16] Michael D. Wilson,et al. Cooperativity and Rapid Evolution of Cobound Transcription Factors in Closely Related Mammals , 2013, Cell.
[17] C. Danko,et al. Enhancer transcripts mark active estrogen receptor binding sites , 2013, Genome research.
[18] D. Reed,et al. QTL Analysis of Dietary Obesity in C57BL/6byj X 129P3/J F2 Mice: Diet- and Sex-Dependent Effects , 2013, PloS one.
[19] L. Aaltonen,et al. Lessons from functional analysis of genome-wide association studies. , 2013, Cancer research.
[20] Kyoung-Jae Won,et al. EBF2 determines and maintains brown adipocyte identity. , 2013, Cell metabolism.
[21] Tanya M. Teslovich,et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.
[22] M. Nóbrega,et al. Regulatory variation in a TBX5 enhancer leads to isolated congenital heart disease. , 2012, Human molecular genetics.
[23] Jussi Paananen,et al. Hyperglycemia and a Common Variant of GCKR Are Associated With the Levels of Eight Amino Acids in 9,369 Finnish Men , 2012, Diabetes.
[24] Matthew T. Maurano,et al. Widespread Site-Dependent Buffering of Human Regulatory Polymorphism , 2012, PLoS genetics.
[25] Noboru Jo Sakabe,et al. Transcriptional enhancers in development and disease , 2012, Genome Biology.
[26] Thomas M. Keane,et al. Mouse genomic variation and its effect on phenotypes and gene regulation , 2011, Nature.
[27] G. Siuzdak,et al. Metabolomics annotates ABHD3 as a physiologic regulator of medium-chain phospholipids , 2011, Nature chemical biology.
[28] Albin Sandelin,et al. Cross species comparison of C/EBPα and PPARγ profiles in mouse and human adipocytes reveals interdependent retention of binding sites , 2011, BMC Genomics.
[29] Logan J Everett,et al. Species-specific strategies underlying conserved functions of metabolic transcription factors. , 2011, Molecular endocrinology.
[30] T. Mikkelsen,et al. Comparative Epigenomic Analysis of Murine and Human Adipogenesis , 2010, Cell.
[31] Olle Melander,et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus , 2010, Nature.
[32] C. Glass,et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.
[33] Michael D. Wilson,et al. Five-Vertebrate ChIP-seq Reveals the Evolutionary Dynamics of Transcription Factor Binding , 2010, Science.
[34] Jonathan Schug,et al. Propagation of adipogenic signals through an epigenomic transition state. , 2010, Genes & development.
[35] G. Tuteja,et al. Cell-Specific Determinants of Peroxisome Proliferator-Activated Receptor γ Function in Adipocytes and Macrophages , 2010, Molecular and Cellular Biology.
[36] Serban Nacu,et al. Fast and SNP-tolerant detection of complex variants and splicing in short reads , 2010, Bioinform..
[37] Kyle J. Gaulton,et al. A map of open chromatin in human pancreatic islets , 2010, Nature Genetics.
[38] Dorothy D. Sears,et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization , 2009, Proceedings of the National Academy of Sciences.
[39] H. Stunnenberg,et al. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. , 2008, Genes & development.
[40] Jonathan Schug,et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. , 2008, Genes & development.
[41] R. Korstanje,et al. Candidate genes for obesity revealed from a C57BL/6J × 129S1/SvImJ intercross , 2008, International Journal of Obesity.
[42] Vip Viprakasit,et al. A Regulatory SNP Causes a Human Genetic Disease by Creating a New Transcriptional Promoter , 2006, Science.
[43] C. Kahn,et al. Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. , 2004, Diabetes.
[44] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.
[45] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[46] B. Shastry,et al. SNP alleles in human disease and evolution , 2002, Journal of Human Genetics.
[47] S. O’Rahilly,et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.
[48] W. Wahli,et al. DNA Binding Properties of Peroxisome Proliferator-activated Receptor Subtypes on Various Natural Peroxisome Proliferator Response Elements , 1997, The Journal of Biological Chemistry.
[49] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[50] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[51] H. Green,et al. QUANTITATIVE STUDIES OF THE GROWTH OF MOUSE EMBRYO CELLS IN CULTURE AND THEIR DEVELOPMENT INTO ESTABLISHED LINES , 1963, The Journal of cell biology.
[52] C. Stoeckert,et al. PPAR (cid:1) and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale , 2008 .
[53] E S Lander,et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. , 2000, Nature genetics.
[54] J. Lehmann,et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.